Zoledronic acid
Approved · EMAAlso known as (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid, (1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid, Reclast, Zometa+1 more
(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid, (1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid, Reclast, Zometa, ácido zoledrónico.
Recent clinical, regulatory, research and industry developments relating to this drug.
Program of Continuous Passive Motion Exercises Against Heterotopic Ossification
Market withdrawal: Zoledronic acid medac (EMA)
Market withdrawal: Zoledronic acid Actavis (EMA)
Market withdrawal: Zoledronic Acid Hospira (EMA)
Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study.
Approval: Zoledronic Acid Accord (EMA)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced… Show full indicationShow less
Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. Treatment of adult patients with tumour-induced hypercalcaemia (TIH).
Indication: Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced… Show full indicationShow less
Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. Treatment of adult patients with tumour-induced hypercalcaemia.
Indication: 4 mg / 5 ml and 4 mg / 100 ml: Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia)… Show full indicationShow less
4 mg / 5 ml and 4 mg / 100 ml: Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. Treatment of adult patients with tumour-induced hypercalcaemia (TIH). 5 mg / 100 ml: Treatment of osteoporosis: in post-menopausal women; in men; at increased risk of fracture, including those with a recent low-trauma hip fracture. Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: in post-menopausal women; in men; at increased risk of fracture. Treatment of Paget's disease of the bone in adults.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Innovative Approach to Geriatric Osteoporosis
The Impact of Osteoporosis Medications on Muscle Health in Older Adults
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes3
Journals, researchers & institutions
- BoneKEy reports1
- Breast (Edinburgh, Scotland)1
- Clinical cancer research : an official journal of the American Association for Cancer Research1
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America1
- Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology1
- Aftring RP1
- Anderson KC1
- Antunez-Flores O1
- Argonza-Aviles E1
- Atherton PJ1
- Bachiller-Corral J1
- Badros A1
- Brown JP1
- Aarhus University Hospital1
- Atlanta Department of Veterans Affairs Medical Center1
- Cedars-Sinai Samuel Oschin Comprehensive Cancer Center1
- Dana-Farber/Partners Cancer Care Institute1
- Emory University School of Medicine.1
- Hospital Ramon Y Cajal1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.